Welcome to our dedicated page for Currenc Group news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group stock.
Currenc Group Inc. reports developments in its fintech business, including AI tools for financial institutions and digital remittance services associated with Tranglo and WalletKu. Company updates commonly cover processing activity, remittance revenue, airtime-transfer exposure, operating results, and cost management.
News also includes governance and capital-structure matters for CURR ordinary shares, material agreements, shareholder meeting items, Nasdaq listing-compliance notices, and disclosures tied to the tokenization of ordinary shares. The company is described in its public updates as a Cayman Islands exempted company with securities listed on Nasdaq.
Sera Labs, a subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), has launched ImmunD₃, an oral thin-film strip delivering a weekly dose of 40,000 IU of Vitamin D. This innovation is part of the Nutri-Strips™ line aimed at enhancing convenience in vitamin supplementation. The product is supported by a new e-commerce website and a national TV advertising campaign. Vitamin D's role in immune health is highlighted, with a study indicating that 82.2% of COVID-19 patients were Vitamin D deficient. Sera Labs continues to develop products across health, wellness, beauty, and pets.
Summary not available.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that CEO Rob Davidson will present at NobleCon17, an institutional investor conference, on January 19 at 3:00 p.m. EST. He will discuss CURE's global health leadership, recent acquisition of Sera Labs, and updates on the approved Investigational New Drug application for CUREfilm Blue™ to treat erectile dysfunction. Davidson emphasized the company's strong distribution and marketing strategies. Attendees can register for the conference for free, and a video of the presentation will be available on CURE's website the next day.
CURE Pharmaceutical Holding Corp (OTC: CURR) announced that CEO Rob Davidson will present at the H.C. Wainwright BioConnect 2021 Virtual Conference on January 11, 2021. The presentation will discuss CURE's acquisition of Sera Labs, enhancing global health and wellness positioning through new distribution channels. Davidson will also highlight the recently approved Investigational New Drug application for CUREfilm Blue™ aimed at treating erectile dysfunction. This event marks a pivotal period for CURE as they expand operations and explore new opportunities.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has received FDA approval for its Investigational New Drug (IND) application for CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This product is being developed using the CUREfilm™ technology, which offers a convenient alternative to traditional pills. The global ED drug market is projected to reach USD $6.6 billion by 2025, presenting significant market potential for CUREfilm Blue™. This milestone validates CURE's technology and opens opportunities for further clinical trials.
CURE Pharmaceutical Holdings (OTCQB: CURR) will present at the LD Micro Main Event Conference on December 15, 2020, at 11:00 AM PT. A video webcast for investors is scheduled for December 17, 2020, at 4:00 PM ET, featuring key executives discussing the company's strategic positioning. Shareholders can submit questions via email by December 15 at 6 PM ET for potential answers during the webcast. Archived versions will also be available post-event. The company focuses on innovative pharmaceutical technology and wellness products, with international partnerships for manufacturing.